CoChat

A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial

Open access
Illingworth, D. Roger, Crouse III, John R., Hunninghake, Donald B., Davidson, Michael H., Escobar, Ivan D., Stalenhoef, Anton F. H., Paragh, Gyorgy, S., Patrick T., Liu, Minzhi, Melino, Michael R., O'Grady, Laura, Mercuri, Michele, Mitchel, Yale B. · 2001 · Current Medical Research and Opinion
Cited by 90

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: At higher doses, simvastatin has been shown to produce significantly greater increases in high-density lipoprotein (HDL) cholesterol and apolipoprotein (apo) A-I than atorvastatin. To extend and confirm these findings, a 36-week, randomized, double-blind, dose-titration study was performed in 826 hypercholesterolemic patients to compare the effects of simvastatin and atorvastatin on HDL cholesterol, apo A-I, and clinical and laboratory safety. PRIMARY HYPOTHESIS: Simvastatin, across a range of doses, will be more effective than atorvastatin at raising HDL cholesterol and apo A-I levels. METHODS: A total of 826 hypercholesterolemic patients were enrolled in this double-blind, randomized, parallel, 36-week, dose-escalation study. Patients randomized to simvastatin received 40 mg/day for the first 6 weeks, 80 mg/day for the next 6 weeks, and remained on 80 mg/day for the final 24 weeks. Patients randomized to atorvastatin received 20 mg/day for the first 6 weeks, 40 mg/day for the next 6 weeks, and 80 mg/day for the remaining 24 weeks. RESULTS: During the first 12 weeks of the study, simvastatin increased HDL cholesterol and apo A-I more than the comparative doses of atorvastatin, while producing slightly lower reductions in low-density lipoprotein (LDL) cholesterol and triglycerides. At the maximal dose comparison, simvastatin 80 mg and atorvastatin 80 mg, the HDL cholesterol and apo A-I differences favoring simvastatin were larger than at the lower doses. In addition, at the maximal dose comparison, the incidence of drug-related clinical adverse experiences was approximately two-fold higher with atorvastatin 80 mg than with simvastatin 80 mg (23 versus 12%, p < 0.001), due predominantly to a greater incidence of gastrointestinal symptoms with atorvastatin (10 versus 3%, p < 0.001). The incidence of clinically significant alanine aminotransferase elevations was also higher with atorvastatin 80 mg than with simvastatin 80 mg (3.8 versus 0.5%, p < 0.010), especially in women (6.0 versus 0.6%). CONCLUSIONS: At the doses compared in this study, simvastatin led to greater increases in HDL cholesterol and apo A-I levels than atorvastatin. At the maximum dose comparison, there were fewer drug-related gastrointestinal symptoms and clinically significant aminotransferase elevations with simvastatin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1185/03007990152005351

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 90

Metadata

Authors
Illingworth, D. R., Crouse III, J. R., Hunninghake, D. B., Davidson, M. H., Escobar, I. D., Stalenhoef, A. F. H., Paragh, G., S., P. T., Liu, M., Melino, M. R., O'Grady, L., Mercuri, M., & Mitchel, Y. B.
Venue
Current Medical Research and Opinion
Published
2001-05-30
Volume
17
Issue
1
Pages
43-50
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2030357298
Cited by
90
References
7
FWCI
10.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial. https://app.cochat.ai/papers/10.1185/03007990152005351
The paper
Illingworth, D. R., Crouse III, J. R., Hunninghake, D. B., Davidson, M. H., Escobar, I. D., Stalenhoef, A. F. H., Paragh, G., S., P. T., Liu, M., Melino, M. R., O'Grady, L., Mercuri, M., & Mitchel, Y. B. (2001). A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial. Current Medical Research and Opinion. https://doi.org/10.1185/03007990152005351

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.